These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 19178487)

  • 1. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
    Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
    Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
    Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
    J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ingenol mebutate gel for actinic keratosis.
    Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
    N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results.
    Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Larsson T; Swanson N
    J Drugs Dermatol; 2014 Jun; 13(6):741-7. PubMed ID: 24918567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results.
    Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Goncalves J; Larsson T; Skov T; Swanson N
    J Drugs Dermatol; 2014 Feb; 13(2):154-60. PubMed ID: 24509965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
    Keating GM
    Drugs; 2012 Dec; 72(18):2397-405. PubMed ID: 23231025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice.
    Bettencourt MS
    J Drugs Dermatol; 2014 Mar; 13(3):269-73. PubMed ID: 24595570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses.
    Lebwohl M; Shumack S; Stein Gold L; Melgaard A; Larsson T; Tyring SK
    JAMA Dermatol; 2013 Jun; 149(6):666-70. PubMed ID: 23553119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP).
    Tzogani K; Nagercoil N; Hemmings RJ; Samir B; Gardette J; Demolis P; Salmonson T; Pignatti F
    Eur J Dermatol; 2014; 24(4):457-63. PubMed ID: 25115145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ingenol mebutate: an introduction.
    Fallen RS; Gooderham M
    Skin Therapy Lett; 2012 Feb; 17(2):1-3. PubMed ID: 22358305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes.
    Augustin M; Tu JH; Knudsen KM; Erntoft S; Larsson T; Hanke CW
    J Am Acad Dermatol; 2015 May; 72(5):816-21. PubMed ID: 25770879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT.
    Berman B; Nestor MS; Newburger J; Park H; Swenson N
    J Drugs Dermatol; 2014 Nov; 13(11):1353-6. PubMed ID: 25607702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ingenol mebutate: a new option for actinic keratosis treatment.
    Gras J
    Drugs Today (Barc); 2013 Jan; 49(1):15-22. PubMed ID: 23362492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas.
    Bucko AD; Jarratt M; Stough DB; Kyhl L; Villumsen J; Hall A
    J Dermatolog Treat; 2018 Feb; 29(1):74-79. PubMed ID: 28524709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
    Berman B
    Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis.
    Jim On SC; Haddican M; Yaroshinsky A; Singer G; Lebwohl M
    Cutis; 2015 Jan; 95(1):47-51. PubMed ID: 25671445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Efficacy and Irritation of Ingenol Mebutate Gel 0.015% Used With or Without Dimethicone Lotion for Treatment of Actinic Keratosis on the Face.
    Jim On SC; Hashim PW; Nia JK; Lebwohl MG
    J Drugs Dermatol; 2017 May; 16(5):432-436. PubMed ID: 28628678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response.
    Rosen RH; Gupta AK; Tyring SK
    J Am Acad Dermatol; 2012 Mar; 66(3):486-93. PubMed ID: 22055282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial.
    Erlendsson AM; Karmisholt KE; Haak CS; Stender IM; Haedersdal M
    J Am Acad Dermatol; 2016 Apr; 74(4):709-15. PubMed ID: 26810403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ingenol mebutate gel in field treatment of actinic keratosis on full face, balding scalp, or approximately 250 cm
    Hanke CW; Albrecht L; Skov T; Larsson T; Østerdal ML; Spelman L
    J Am Acad Dermatol; 2020 Mar; 82(3):642-650. PubMed ID: 31374304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.